AstraZeneca advances ispronicline into Phase IIb ADHD trials
This article was originally published in Scrip
Executive Summary
AstraZeneca plans to start Phase IIb trials of ispronicline (AZD3480) for attention deficit hyperactivity disorder. This announcement triggers a $10 million milestone payment to US-based Targacept, who has licensed the drug to AstraZeneca.